184 related articles for article (PubMed ID: 9707351)
1. Steady-state pharmacokinetics of propranolol enantiomers in healthy male volunteers.
Paradiso-Hardy FL; Walker SE; Bowles SK
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):370-5. PubMed ID: 9707351
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective increase of plasma concentrations of the enantiomers of propranolol and atenolol during exercise.
Stoschitzky K; Kahr S; Donnerer J; Schumacher M; Luha O; Maier R; Klein W; Lindner W
Clin Pharmacol Ther; 1995 May; 57(5):543-51. PubMed ID: 7768077
[TBL] [Abstract][Full Text] [Related]
3. Protein binding of indobufen enantiomers: pharmacokinetics of free fraction-studies after single or multiple doses of rac-indobufen.
Główka FK; Caldwell J
Chirality; 2002 Oct; 14(9):736-41. PubMed ID: 12237835
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective inhibitory effect of nicardipine on the hepatic clearance of propranolol in man.
Vercruysse I; Belpaire F; Wynant P; Massart DL; Dupont AG
Chirality; 1994; 6(1):5-10. PubMed ID: 8018468
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic data of propranolol enantiomers in a comparative human study with (S)- and (R,S)-propranolol.
Lindner W; Rath M; Stoschitzky K; Semmelrock HJ
Chirality; 1989; 1(1):10-3. PubMed ID: 2642031
[TBL] [Abstract][Full Text] [Related]
6. Age and gender influence the stereoselective pharmacokinetics of propranolol.
Gilmore DA; Gal J; Gerber JG; Nies AS
J Pharmacol Exp Ther; 1992 Jun; 261(3):1181-6. PubMed ID: 1602383
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of reboxetine in healthy male volunteers.
Denolle T; Pellizzoni C; Jannuzzo MG; Poggesi I
Clin Pharmacol Ther; 1999 Sep; 66(3):282-7. PubMed ID: 10511064
[TBL] [Abstract][Full Text] [Related]
8. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat.
Bode W; Toet AE; Stolker AA; van Ginkel LA; Groen K; Wemer J; de Wildt DJ
Chirality; 1995; 7(8):626-31. PubMed ID: 8593256
[TBL] [Abstract][Full Text] [Related]
9. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
Cerqueira PM; Cesarino EJ; Mateus FH; Mere Y; Santos SR; Lanchote VL
Chirality; 1999; 11(7):591-7. PubMed ID: 10423287
[TBL] [Abstract][Full Text] [Related]
10. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations, and influence on thyroid hormone levels.
Stoschitzky K; Lindner W; Egginger G; Brunner F; Obermayer-Pietsch B; Passath A; Klein W
Clin Pharmacol Ther; 1992 Apr; 51(4):445-53. PubMed ID: 1563214
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of reboxetine enantiomers in the dog.
Frigerio E; Benecchi A; Brianceschi G; Pellizzoni C; Poggesi I; Strolin Benedetti M; Dostert P
Chirality; 1997; 9(3):303-6. PubMed ID: 9176997
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective features of (R)- and (S)-atenolol: clinical pharmacological, pharmacokinetic, and radioligand binding studies.
Stoschitzky K; Egginger G; Zernig G; Klein W; Lindner W
Chirality; 1993; 5(1):15-9. PubMed ID: 8383518
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective disposition of propranolol in rabbits. Role of presystemic organs and dose.
Marier JF; Pichette V; du Souich P
Drug Metab Dispos; 1998 Feb; 26(2):164-9. PubMed ID: 9456303
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study.
Egginger G; Lindner W; Kahr S; Stoschitzky K
Chirality; 1993; 5(7):505-12. PubMed ID: 8240927
[TBL] [Abstract][Full Text] [Related]
15. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers.
Gumbhir-Shah K; Kellerman DJ; DeGraw S; Koch P; Jusko WJ
J Clin Pharmacol; 1998 Dec; 38(12):1096-106. PubMed ID: 11301561
[TBL] [Abstract][Full Text] [Related]
17. Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children.
Kauffman RE; Lieh-Lai MW; Uy HG; Aravind MK
Clin Pharmacol Ther; 1999 Apr; 65(4):382-8. PubMed ID: 10223774
[TBL] [Abstract][Full Text] [Related]
18. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.
Ericsson H; Schwieler J; Lindmark BO; Löfdahl P; Thulin T; Regårdh CG
Chirality; 2001; 13(3):130-4. PubMed ID: 11270321
[TBL] [Abstract][Full Text] [Related]
19. [The pharmacokinetics of propranolol and its conjugated metabolites in patients with chronic ischemic heart disease and arterial hypertension with a one-time and course intake of the drug].
Belolipetskaia VG; Rumiantsev DS; Piotrovskiĭ VK; Metelitsa VI; Duda SG; Ostrovskaia TP; Kokurina EV; Martseva SIu; Bochkareva EV; Filatova NP
Eksp Klin Farmakol; 1995; 58(6):56-9. PubMed ID: 8704616
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis.
Glówka FK; Strzelecka D; Zapalski S
Chirality; 2001 Jun; 13(6):308-12. PubMed ID: 11370020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
